Latest News in the pharma Industry

Research & Development

Lilly's Taltz shows promise for patients with active psoriatic arthritis

Lilly's Taltz shows promise for patients with active psoriatic arthritis

15 Jun 2017

Demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors.

Read more 
LifeArc, previously MRC Technology, set to transform the medical research landscape

LifeArc, previously MRC Technology, set to transform the medical research landscape

15 Jun 2017

Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases.

Read more 
Irvine Scientific adds new Center of Excellence for R&D

Irvine Scientific adds new Center of Excellence for R&D

14 Jun 2017

Company adds fifth building in Southern California.

Read more 
Successful Phase III top-line results with Bekinda for acute gastroenteritis

Successful Phase III top-line results with Bekinda for acute gastroenteritis

14 Jun 2017

Study successfully met its primary endpoint and Bekinda 24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and gastritis.

Read more 
Achelios Therapeutics concludes successful Type C meeting with FDA regarding Topofen

Achelios Therapeutics concludes successful Type C meeting with FDA regarding Topofen

14 Jun 2017

Currently there are no approved topical NSAIDs indicated for the treatment of migraine.

Read more 
Lilly's galcanezumab significantly reduces number of migraine headache days

Lilly's galcanezumab significantly reduces number of migraine headache days

12 Jun 2017

New results presented at AHS.

Read more 
Lilly announces strategic collaboration with KeyBioscience

Lilly announces strategic collaboration with KeyBioscience

8 Jun 2017

Collaboration to focus on a potential new class of treatments for metabolic disorders.

Read more 
FDA Advisory Committee to review Avastin biosimilar candidate

FDA Advisory Committee to review Avastin biosimilar candidate

7 Jun 2017

The Committee will review analytical, pharmacokinetic and clinical data from studies involving ABP 215, including results from a Phase III study in patients with NSCLC.

Read more 
New BMS collaboration to evaluate combination therapy in colorectal cancer

New BMS collaboration to evaluate combination therapy in colorectal cancer

6 Jun 2017

Phase I/II study to evaluate the combination of Opdivo (nivolumab) and Opdivo +Yervoy (ipilimumab) regimen with Mekinist (trametinib) in patients with colorectal cancer.

Read more 
Combination therapy shown to shrink tumours in many patients whose cancer has spread to the brain

Combination therapy shown to shrink tumours in many patients whose cancer has spread to the brain

5 Jun 2017

Combination of nivolumab plus ipilimumab can fundamentally change survival expectations.

Read more 
Spinraza approved in the EU as first treatment for spinal muscular atrophy

Spinraza approved in the EU as first treatment for spinal muscular atrophy

2 Jun 2017

Robust data from Phase III studies demonstrated positive impact on motor milestone achievement; increased survival in infants with SMA.

Read more 
NICE approves first use of Opdivo in blood cancer

NICE approves first use of Opdivo in blood cancer

2 Jun 2017

NICE has recommended immunotherapy drug nivolumab for the treatment of adult patients with classical Hodgkin lymphoma.

Read more